ADAPT Data Linking Naproxen To Heart Risk Is “Not Reliable” – Nissen
This article was originally published in The Tan Sheet
Executive Summary
The premature halting of the ADAPT trial and subsequent safety concerns for naproxen were "inappropriate and reflected faulty logic," according to Cleveland Clinic cardiologist Steven Nissen, MD
You may also be interested in...
Traditional NSAIDs Do Not Raise Cardiovascular Risk – JAMA Review
The nonselective NSAIDs naproxen and ibuprofen appear neither to increase nor decrease the risk of cardiovascular events, according to a Journal of the American Medical Association data review published online Sept. 12
Naproxen Heart Concerns Surface In Halted NIH Alzheimer’s Trial
The OTC industry is taking a wait-and-see approach regarding concerns about cardiovascular risks of naproxen (Bayer's Aleve) and other older NSAIDs rising in the wake of COX-2-related safety issues
Avoiding GMP “Showstoppers” Keeps Manufacturers Off FDA’s “Radar”
Compliance consultants warn that certain dietary supplement good manufacturing practices violations are inspection "showstoppers" and will draw agency enforcement